What happened
- A team of 21 researchers published on 3 November 2026 in Nature Communications a study of antibodies against nerve tissue in people with schizophrenia spectrum disorders.
- They analysed the cerebrospinal fluid of 32 participants with these disorders and 32 controls without neuropsychiatric conditions, as well as their blood plasma.
- They used several complementary techniques: brain tissue staining, immunoprecipitation with mass spectrometry, phage display sequencing and protein microarrays.
- They identified three rare autoantibodies. One of them targets alpha-crystallin B, a protein present in the nervous system.
Why it matters
- Schizophrenia has a substantial genetic load, but its stable incidence and clinical diversity leave room for non-genetic mechanisms.
- Autoimmune encephalitis has already shown that antibodies against nerve tissue can cause psychosis. However, the antibodies typical of that encephalitis are uncommon in schizophrenia.
- The study suggests that other, rarer autoantibodies exist that standard tests do not look for.
The number
3. That is the number of autoantibodies against nerve tissue the team identified in people with schizophrenia spectrum disorders.
Context
The antibody against alpha-crystallin B has a particular feature: it preferentially recognises the protein when it is phosphorylated at serine 45, a specific chemical modification. That antibody did not appear in the cerebrospinal fluid of people with untreated multiple sclerosis, a disease in which antibodies against the unphosphorylated form of the same protein are frequent. The difference suggests it is not the same autoimmune phenomenon.
The authors are cautious. They say their findings do not define autoimmune psychosis as a new disease, but they do support broader searches for autoantibodies in psychotic disorders. The sample size, 32 people per group, also means the results need confirming in larger groups.
At Mamífero we follow research on mental health and neurology. We reported that a study in Sydney found a circadian subtype of depression and that Alzheimer-like changes in 14% of ALS patients were linked to shorter survival. Also that using omeprazole for more than six months was linked to more Parkinson’s in a Korean cohort and that a clade of enterovirus D68 tracks cases of acute flaccid myelitis.
What’s next
- The results need to be replicated in larger groups and other populations.
- It remains unknown whether these antibodies contribute to symptoms or mark another process.
- If confirmed, they could guide the study of patient subgroups with an immune component.
Bottom line
In a minority of people with schizophrenia, the immune system appears to recognise proteins of the nervous system itself. The study does not change the diagnosis, but it opens a question worth investigating.
Sources
- Pandit, P., Listwak, S., Ngo, T. et al., “Neural autoantibodies in the cerebrospinal fluid of individuals with schizophrenia spectrum disorders”, Nature Communications, 3 November 2026, DOI 10.1038/s41467-026-78783-4. This note is based on the paper’s abstract.
- Cover image: James Heilman, MD, CC BY 3.0, via Wikimedia Commons
Edited by Rodrigo Cornejo. How we select and verify: who writes these notes.
